VolitionRx Granted Its First U.S. Patent

NAMUR, Belgium, Sept. 10, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood tests for a broad range of cancer types and other conditions, today announced the grant of US Patent Number 9,128,086 entitled "Detection of Histone Modification in Cell-Free Nucleosomes". This patent is already issued in Europe to the Company under the number EP1668368B1.

The key new U.S. patent, issued yesterday and expiring in mid-2029, relates to the detection of epigenetic changes that affect chromosome structure in cancer, by means of a simple test using a single drop of blood. VolitionRx's Nucleosomics® platform detects changes to histone proteins contained in fragments of chromosomes, called nucleosomes, that circulate in the blood of cancer patients.

Dr. Jake Micallef, Chief Scientific Officer of VolitionRx, remarked, "VolitionRx is building a world-wide portfolio of intellectual property to protect its Nucleosomics® technology for detecting cancer and other diseases in blood samples and biological fluids. The grant of U.S. Patent 9,128,086 provides protection to key technology that underpins our NuQ® tests as we continue towards our goals of commercialization and helping as many patients as possible."

Cameron Reynolds, Chief Executive Officer of VolitionRx, added, "Our first granted patent in the U.S. is a key milestone for VolitionRx in our path to commercialization of our proprietary Nucleosomics® platform. Since the Company's inception, our mission has been to develop accurate and cost-effective detection tools for early-stage cancer and other conditions. We have made great progress through exhaustive work in R&D and clinical trials. The grant of this broad-reaching, wholly-owned and royalty-free patent is a critical step in protecting VolitionRx's intellectual property and consequently shareholder value."

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream -- an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

Media Contacts
Anita Heward, VolitionRx
a.heward@volitionrx.com 
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014

Investor Contacts
Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com 
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests" and similar expressions identify forward-looking statements.  These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-granted-its-first-us-patent-300140698.html

SOURCE VolitionRx Ltd

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus